AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31587090 — intervention group
Group type: EXPERIMENTAL
Intervention: Model-based dosing (Group 2)
Number of subjects: 31
Study 31587090 — intervention group
Group type: COMPARATOR
Intervention: Conventional dosing (Group 2)
Number of subjects: 31
Study 30591672 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy lifestyle intervention
Number of subjects: 220
Study 30591672 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 220
Study 27737352 — intervention group
Group type: EXPERIMENTAL
Intervention: Colgate Luminous White (G1)
Number of subjects: 60
Study 27737352 — intervention group
Group type: EXPERIMENTAL
Intervention: Close Up White Now (G2)
Number of subjects: 60
Study 27737352 — intervention group
Group type: COMPARATOR
Intervention: Sorriso dentifrice (G3-control)
Number of subjects: 60
Study 25643509 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 1200 mg daily divided into 3 doses for 7 days
Number of subjects: 50
Study 25643509 — intervention group
Group type: COMPARATOR
Intervention: Lactulose syrup (laxolac) 90 ml daily divided into 3 doses for 7 days
Number of subjects: 50
Study 22327752 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-abdominal insufflation pressure under 10 mm Hg with infiltrative bupivacaine (LPBG)
Number of subjects: 473
Study 22327752 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal insufflation pressure 15 mm Hg with no infiltrative bupivacaine (HPNBG)
Number of subjects: 473
Study 22327752 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal insufflation pressure 15 mm Hg with infiltrative bupivacaine (HPBG)
Number of subjects: 473
Study 22327752 — intervention group
Group type: COMPARATOR
Intervention: Intra-abdominal insufflation pressure under 10 mm Hg with no infiltrative bupivacaine (LPNBG)
Number of subjects: 473
Study 20385930 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranolazine
Number of subjects: 2291
Study 20385930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2291
Study 17371829 — intervention group
Group type: EXPERIMENTAL
Intervention: DX-619 (800 mg, intravenous, once daily for 4 days)
Number of subjects: 41
Study 17371829 — intervention group
Group type: COMPARATOR
Intervention: Placebo (intravenous, once daily for 4 days)
Number of subjects: 41
Study 16015059 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass surgery
Number of subjects: 0
Study 16015059 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty
Number of subjects: 0
Study 16015059 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization (general)
Number of subjects: 0
Study 16015059 — intervention group
Group type: COMPARATOR
Intervention: Noninvasive therapy
Number of subjects: 0
Study 12566753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide (250 mg per day)
Number of subjects: 84
Study 12566753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide plus oral contraceptive (250 mg flutamide + 35 microg ethinyl estradiol + 2 mg cyproterone acetate per day)
Number of subjects: 84
Study 12566753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide plus oral contraceptive
Number of subjects: 84
Study 12566753 — intervention group
Group type: EXPERIMENTAL
Intervention: Flutamide
Number of subjects: 84
Study 9699773 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 93
Study 9699773 — intervention group
Group type: COMPARATOR
Intervention: Other tocolytics
Number of subjects: 93
Study 8077535 — intervention group
Group type: EXPERIMENTAL
Intervention: Bovine collagen application for puncture site closure after sheath removal immediately after angioplasty
Number of subjects: 124
Study 8077535 — intervention group
Group type: COMPARATOR
Intervention: Delayed sheath removal followed by manual compression
Number of subjects: 124
Study 2658880 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasogastric decompression (NG)
Number of subjects: 535
Study 2658880 — intervention group
Group type: COMPARATOR
Intervention: No nasogastric decompression
Number of subjects: 535
Study 2658880 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (NG and no NG)
Number of subjects: 535
Study 819984 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (200 mg/Kg i.v. administration) for 15 consecutive days, then once a week for 6 weeks
Number of subjects: 37
Study 819984 — intervention group
Group type: EXPERIMENTAL
Intervention: Taurine (200 mg/Kg i.v. administration)
Number of subjects: 37
Study 31883294 — intervention group
Group type: EXPERIMENTAL
Intervention: Bivalirudin infusion
Number of subjects: 151
Study 31883294 — intervention group
Group type: COMPARATOR
Intervention: Unfractionated heparin (UFH) infusion
Number of subjects: 151
Study 31326223 — intervention group
Group type: EXPERIMENTAL
Intervention: TECNIS Symfony IOL implantation
Number of subjects: 29
Study 28830669 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sodium diet (HS; 300 mmol/d)
Number of subjects: 85
Study 28830669 — intervention group
Group type: COMPARATOR
Intervention: Low-sodium diet (LS; 20 mmol/d)
Number of subjects: 85
Study 25252593 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YAG laser treatment (1W, 100mj, 1064nm)
Number of subjects: 24
Study 25252593 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonic scalers (control group)
Number of subjects: 24
Study 23551409 — intervention group
Group type: EXPERIMENTAL
Intervention: Yangxue Qingnao Granules (YXQNG) 12 g/day
Number of subjects: 273
Study 23551409 — intervention group
Group type: COMPARATOR
Intervention: Nimodipine 30 mg/day
Number of subjects: 273
Study 21300177 — intervention group
Group type: EXPERIMENTAL
Intervention: KAN-DO intervention (mailed family kits encouraging healthy lifestyle change, 8 monthly kits, motivational counseling calls, and a single group session)
Number of subjects: 400
Study 21300177 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 400
Study 19660124 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 17334832 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave lithotripsy (ESWL)
Number of subjects: 30
Study 17334832 — intervention group
Group type: COMPARATOR
Intervention: Pre-ESWL
Number of subjects: 30
Study 15309209 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiotensin converting enzyme inhibitors (ACE inhibitors)
Number of subjects: 0
Study 15309209 — intervention group
Group type: COMPARATOR
Intervention: Thiazide diuretics (high doses)
Number of subjects: 0
Study 15309209 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazide diuretics (lower doses)
Number of subjects: 0
Study 15309209 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium channel blockers
Number of subjects: 0
Study 15309209 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors (in general)
Number of subjects: 0
Study 15309209 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 11913304 — intervention group
Group type: EXPERIMENTAL
Intervention: ARM & HAMMER Dental Care The Baking Soda Gum (AHDC) - sugar-free chewing gum, 2 pieces, twice a day for 20 minutes
Number of subjects: 78
Study 11913304 — intervention group
Group type: COMPARATOR
Intervention: breath mints (study placebo), twice a day
Number of subjects: 78
Study 9214067 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check-up with written feedback from the general practitioner
Number of subjects: 1370
Study 9214067 — intervention group
Group type: EXPERIMENTAL
Intervention: Health check-up with written feedback and opportunity for health discussions
Number of subjects: 1370
Study 9214067 — intervention group
Group type: EXPERIMENTAL
Intervention: Health discussions with general practitioner
Number of subjects: 1370
Study 9214067 — intervention group
Group type: COMPARATOR
Intervention: Health check-up
Number of subjects: 1370
Study 9214067 — intervention group
Group type: COMPARATOR
Intervention: Health discussions
Number of subjects: 1370
Study 8260118 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous sulphonylurea therapy (glibenclamide for 16 weeks)
Number of subjects: 0
Study 8260118 — intervention group
Group type: COMPARATOR
Intervention: Intermittent sulphonylurea therapy (glibenclamide for 2 weeks then placebo for 2 weeks for 16 weeks)
Number of subjects: 0
Study 3733281 — intervention group
Group type: EXPERIMENTAL
Intervention: Buffered preparations
Number of subjects: 6
Study 3733281 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric-coated tablet
Number of subjects: 6
Study 3733281 — intervention group
Group type: COMPARATOR
Intervention: Plain compressed aspirin
Number of subjects: 6
Study 28750586 — intervention group
Group type: EXPERIMENTAL
Intervention: Powered ankle prosthesis (BiOM T2 Ankle System)
Number of subjects: 20
Study 28750586 — intervention group
Group type: COMPARATOR
Intervention: Participants classified as K4 (highest function)
Number of subjects: 20
Study 26941013 — intervention group
Group type: EXPERIMENTAL
Intervention: Watchful waiting
Number of subjects: 198
Study 26941013 — intervention group
Group type: COMPARATOR
Intervention: Immediate antibiotics
Number of subjects: 198
Study 25269491 — intervention group
Group type: EXPERIMENTAL
Intervention: INCLUSIVE intervention
Number of subjects: 6000
Study 25269491 — intervention group
Group type: COMPARATOR
Intervention: Normal practice
Number of subjects: 6000
Study 22988682 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.454% stannous fluoride dentifrice
Number of subjects: 200
Study 22988682 — intervention group
Group type: COMPARATOR
Intervention: 0.30% triclosan positive control
Number of subjects: 200
Study 20629096 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal aberrations in UUT‐UC specimens from dialysis patients
Number of subjects: 27
Study 20629096 — intervention group
Group type: EXPERIMENTAL
Intervention: High-stage and high-grade tumors
Number of subjects: 27
Study 20629096 — intervention group
Group type: EXPERIMENTAL
Intervention: Female ESRD patients with UUT‐UC
Number of subjects: 27
Study 17598653 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin XL 80 mg/d for 4 weeks
Number of subjects: 37
Study 17598653 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy volunteers)
Number of subjects: 37
Study 15858933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (200 mg/day) with aspirin (100 mg/day)
Number of subjects: 184
Study 15858933 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine (200 mg/day) with aspirin (100 mg/day)
Number of subjects: 184
Study 15858933 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol
Number of subjects: 184
Study 15858933 — intervention group
Group type: COMPARATOR
Intervention: Ticlopidine
Number of subjects: 184
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP monohydrate + water
Number of subjects: 65
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP trihydrate + water
Number of subjects: 65
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP tetrahydrate + water
Number of subjects: 65
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP monohydrate + hydrogen peroxide (HP)
Number of subjects: 65
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP trihydrate + HP
Number of subjects: 65
Study 12059914 — intervention group
Group type: EXPERIMENTAL
Intervention: SP tetrahydrate + HP
Number of subjects: 65
Study 12059914 — intervention group
Group type: COMPARATOR
Intervention: Control teeth (not treated with sodium perborate)
Number of subjects: 65
Study 7644776 — intervention group
Group type: EXPERIMENTAL
Intervention: Zardaverine (1.5 mg, 3.0 mg, or 6.0 mg)
Number of subjects: 10
Study 7644776 — intervention group
Group type: COMPARATOR
Intervention: Salbutamol (0.3 mg)
Number of subjects: 10
Study 7644776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2491362 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily
Number of subjects: 230
Study 2491362 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily
Number of subjects: 230
Study 1259126 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl (0.01 mg/kg, n = 7)
Number of subjects: 16
Study 1259126 — intervention group
Group type: EXPERIMENTAL
Intervention: Althesin (0.075 mg/kg, n = 9)
Number of subjects: 16
Study 31864809 — intervention group
Group type: EXPERIMENTAL
Intervention: DL optimization algorithm (group C)
Number of subjects: 70
Study 31864809 — intervention group
Group type: COMPARATOR
Intervention: Group A (80 kVp)
Number of subjects: 70
Study 31864809 — intervention group
Group type: COMPARATOR
Intervention: Group C (DL optimization)
Number of subjects: 70
Study 31864809 — intervention group
Group type: EXPERIMENTAL
Intervention: DL algorithm
Number of subjects: 70
Study 31178967 — intervention group
Group type: EXPERIMENTAL
Intervention: PR antioxidant group (α‐tocopherol: 30 mg/day, ascorbate: 180 mg/day, zinc gluconate: 15 mg/day, selenomethionine: 50 μg/day)
Number of subjects: 64
Study 31178967 — intervention group
Group type: COMPARATOR
Intervention: PR placebo group
Number of subjects: 64
Study 28677877 — intervention group
Group type: EXPERIMENTAL
Intervention: BMS-986231 (3, 5, 7 or 12 µg/kg/min)
Number of subjects: 46
Study 28677877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 26960762 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet only (DO, n = 13)
Number of subjects: 43
Study 26960762 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and aerobic exercise (DA, n = 11)
Number of subjects: 43
Study 26960762 — intervention group
Group type: EXPERIMENTAL
Intervention: Diet and combined aerobic-resistance exercise (DC, n = 19)
Number of subjects: 43
Study 26960762 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 43
Study 26960762 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall lifestyle modification (diet with or without exercise)
Number of subjects: 43
Study 23908084 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg flurbiprofen axetil intravenously 15 minutes before surgical incision and 6 hours later (group F)
Number of subjects: 60
Study 23908084 — intervention group
Group type: COMPARATOR
Intervention: Intravenous 5 mL intralipid as a control (group C)
Number of subjects: 60
Study 21983214 — intervention group
Group type: EXPERIMENTAL
Intervention: MF-59-adjuvanted influenza vaccine (Novartis Vaccines)
Number of subjects: 4707
Study 21983214 — intervention group
Group type: COMPARATOR
Intervention: Trivalent inactivated influenza vaccine subunit (GSK)
Number of subjects: 4707
Study 21983214 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 4707
Study 19552905 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive computer assisted instruction (ICAI)
Number of subjects: 84
Study 19552905 — intervention group
Group type: COMPARATOR
Intervention: Instructor-led videotape learning program (IVLP)
Number of subjects: 84
Study 17118810 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires measuring subjective craving (Visual Analogue Scale - VAS)
Number of subjects: 53
Study 17118810 — intervention group
Group type: COMPARATOR
Intervention: Questionnaires measuring anxiety and depression states
Number of subjects: 53
Study 15302236 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV positive patients
Number of subjects: 27
Study 15302236 — intervention group
Group type: COMPARATOR
Intervention: HIV negative patients
Number of subjects: 27
Study 11777291 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 120 mg
Number of subjects: 22
Study 11777291 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 80 mg
Number of subjects: 22
Study 10190709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% (OFLX), 0.25 ml topically bid for 10 days
Number of subjects: 286
Study 10190709 — intervention group
Group type: COMPARATOR
Intervention: Systemic amoxicillin/clavulanate (AUG), 40 mg/kg per day for 10 days
Number of subjects: 286
Study 10190709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% (OFLX)
Number of subjects: 286
Study 10190709 — intervention group
Group type: COMPARATOR
Intervention: Systemic amoxicillin/clavulanate (AUG)
Number of subjects: 286
Study 10190709 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical ofloxacin 0.3% (OFLX) and Systemic amoxicillin/clavulanate (AUG)
Number of subjects: 286
Study 7845792 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT sensor mode
Number of subjects: 6
Study 3052183 — intervention group
Group type: COMPARATOR
Intervention: Captopril (C) 25 mg tid
Number of subjects: 10
Study 3052183 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicardipine (N) 20 mg tid
Number of subjects: 10
Study 3052183 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 10
Study 29292054 — intervention group
Group type: EXPERIMENTAL
Intervention: Beclomethasone 100 mcg plus Formoterol 6 mcg (BDP/F)
Number of subjects: 253
Study 29292054 — intervention group
Group type: COMPARATOR
Intervention: Fluticasone 125 mcg plus Salmeterol 25 mcg (FP/S)
Number of subjects: 253
Study 28895794 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotics (Probinul Neutro, CadiGroup, Rome, Italy), 5 g powder packets dissolved in water three times a day for 30 days
Number of subjects: 36
Study 28895794 — intervention group
Group type: COMPARATOR
Intervention: Placebo, taken at home for 30 days
Number of subjects: 36
Study 26146240 — intervention group
Group type: EXPERIMENTAL
Intervention: Flinders Program plus usual care
Number of subjects: 231
Study 26146240 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 231
Study 23715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Phosphorus mobilization clearance
Number of subjects: 774
Study 23715125 — intervention group
Group type: EXPERIMENTAL
Intervention: Postdialysis central distribution volume
Number of subjects: 774
Study 21317794 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR-652 25 mg
Number of subjects: 0
Study 21317794 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR-652 50 mg
Number of subjects: 0
Study 21317794 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR-652 75 mg
Number of subjects: 0
Study 21317794 — intervention group
Group type: EXPERIMENTAL
Intervention: TBR-652 150 mg
Number of subjects: 0
Study 21317794 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19268976 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa combined with language therapy
Number of subjects: 39
Study 19268976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 39
Study 16813616 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolene Hernia System (PHS)
Number of subjects: 64
Study 16813616 — intervention group
Group type: COMPARATOR
Intervention: Lichtenstein Method
Number of subjects: 64
Study 12775198 — intervention group
Group type: EXPERIMENTAL
Intervention: Supervised physical therapy with a home program
Number of subjects: 84
Study 12775198 — intervention group
Group type: COMPARATOR
Intervention: Home program alone
Number of subjects: 84
Study 10843028 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular ceftriaxone 50 mg/kg
Number of subjects: 172
Study 10843028 — intervention group
Group type: COMPARATOR
Intervention: No second dose of ceftriaxone
Number of subjects: 172
Study 9062488 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 7
Study 9062488 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 7934009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous arm swing with hand-held towels (VAST)
Number of subjects: 16
Study 7934009 — intervention group
Group type: COMPARATOR
Intervention: Normal arm swing (NAS)
Number of subjects: 16
Study 7934009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous arm swing (VAS)
Number of subjects: 16
Study 7934009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous arm swing at NAS heart rate (VNH)
Number of subjects: 16
Study 7934009 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigorous arm swing with hand-held towels at NAS heart rate (VTNH)
Number of subjects: 16
Study 2467496 — intervention group
Group type: EXPERIMENTAL
Intervention: Acrivastine 8 mg t.d.s.
Number of subjects: 10
Study 2467496 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine hydrochloride 20 mg t.d.s.
Number of subjects: 10
Study 2467496 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 30720792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care in Hospitals Program (DCHP) - hospital-wide CI awareness and support education, screening for all patients aged 65+, bedside alert (Cognitive Impairment Identifier)
Number of subjects: 0
Study 30720792 — intervention group
Group type: COMPARATOR
Intervention: Usual hospital care (control)
Number of subjects: 0
Study 30720792 — intervention group
Group type: EXPERIMENTAL
Intervention: Dementia Care in Hospitals Program (DCHP)
Number of subjects: 0
Study 27544607 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stent (DES) implantation
Number of subjects: 97
Study 25535691 — intervention group
Group type: EXPERIMENTAL
Intervention: PWI (+)
Number of subjects: 120
Study 25535691 — intervention group
Group type: COMPARATOR
Intervention: Control (PWI (‐))
Number of subjects: 120
Study 25535691 — intervention group
Group type: COMPARATOR
Intervention: PWI (+) and Control (PWI (‐))
Number of subjects: 120
Study 23558843 — intervention group
Group type: EXPERIMENTAL
Intervention: S(+)‐ketamine
Number of subjects: 140
Study 23558843 — intervention group
Group type: COMPARATOR
Intervention: ropivacaine
Number of subjects: 140
Study 20092882 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination therapy (lithium plus valproate)
Number of subjects: 330
Study 20092882 — intervention group
Group type: COMPARATOR
Intervention: Lithium monotherapy
Number of subjects: 330
Study 20092882 — intervention group
Group type: COMPARATOR
Intervention: Valproate monotherapy
Number of subjects: 330
Study 18447213 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaoshen Fuyin acupuncture therapy combined with language training
Number of subjects: 60
Study 18447213 — intervention group
Group type: COMPARATOR
Intervention: Simple language training
Number of subjects: 60
Study 16628416 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% timolol hydrogel
Number of subjects: 25
Study 16628416 — intervention group
Group type: COMPARATOR
Intervention: 0.5% aqueous timolol
Number of subjects: 25
Study 12711947 — intervention group
Group type: EXPERIMENTAL
Intervention: Internal mammary vessels
Number of subjects: 100
Study 12711947 — intervention group
Group type: COMPARATOR
Intervention: Thoracodorsal vessels
Number of subjects: 100